Cardiff Oncology CAO receives 200,000 option grant

Cardiff Oncology, Inc. reported that Chief Accounting Officer Lindsay Brigitte Ute acquired a grant of 200,000 stock options on February 13, 2026.

Rhea-AI Filing Summary

Cardiff Oncology, Inc. reported that Chief Accounting Officer Lindsay Brigitte Ute acquired a grant of 200,000 stock options on February 13, 2026. The options were granted at an exercise price of $0.00 per share, reflecting a cost-free award rather than an open-market purchase.

Following this transaction, Ute held a total of 1,025,334 stock options directly. According to the vesting terms, 50,000 options vest on February 13, 2027, and 4,166 options vest monthly for the subsequent 36 months, spreading the remainder of the award over three years.

Insider Trade Summary

Grant/Award: 200,000 shares

Grant/Award 1 txn

Insider Lindsay Brigitte Ute

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	200,000	$0.00	$0.00

Holdings After Transaction: Stock Options — 1,025,334 contracts (Direct)

Footnotes (1)

1. F1. 50,000 vest on February 13, 2027 and 4,166 vest monthly for 36 months thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cardiff Oncology (CRDF) report for Lindsay Brigitte Ute?

Cardiff Oncology reported that Chief Accounting Officer Lindsay Brigitte Ute received a grant of 200,000 stock options. The award was recorded as a derivative acquisition rather than a market purchase, with an exercise price of $0.00 per share and a multi-year vesting schedule.

How many stock options were granted to the Cardiff Oncology (CRDF) Chief Accounting Officer?

Lindsay Brigitte Ute was granted 200,000 stock options. These options are part of her equity compensation and increase her directly held option position to 1,025,334 stock options following the transaction, according to the reported post-transaction derivative holdings.

What is the vesting schedule for the 200,000 Cardiff Oncology (CRDF) stock options?

The grant vests over several years. 50,000 options vest on February 13, 2027, and 4,166 additional options vest each month for 36 months thereafter, effectively spreading most of the remaining award across a three-year period.

What exercise price applies to the new Cardiff Oncology (CRDF) stock option grant?

The 200,000 stock options granted to Lindsay Brigitte Ute carry an exercise price of $0.00 per share. This indicates a cost-free option grant structure rather than a purchase of existing shares in the open market.

How many Cardiff Oncology (CRDF) stock options does Lindsay Brigitte Ute hold after this grant?

After the award of 200,000 stock options, Lindsay Brigitte Ute directly holds 1,025,334 stock options. This total reflects her aggregate derivative holdings reported following the February 13, 2026 stock option grant.

Is the Cardiff Oncology (CRDF) Form 4 transaction a stock purchase or an option grant?

The Form 4 reflects an option grant, not a stock purchase. The transaction code is reported as a grant, award, or other acquisition, and covers 200,000 stock options with a $0.00 per share exercise price and structured vesting terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lindsay Brigitte Ute

(Last) (First) (Middle)

11055 FLINTKOTE AVENUE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [ CRDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.6	02/13/2026		A		200,000		(1)	02/13/2036	Common Stock	200,000	$0	1,025,334	D

Explanation of Responses:

1. 50,000 vest on February 13, 2027 and 4,166 vest monthly for 36 months thereafter.

	/s/ Brigitte Lindsay	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.